Cidara Therapeutics (NASDAQ:CDTX – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports.
Separately, HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Cidara Therapeutics in a research note on Monday, April 8th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $93.33.
View Our Latest Stock Analysis on Cidara Therapeutics
Cidara Therapeutics Price Performance
Institutional Investors Weigh In On Cidara Therapeutics
A number of hedge funds have recently added to or reduced their stakes in CDTX. Flagship Harbor Advisors LLC bought a new stake in shares of Cidara Therapeutics during the third quarter valued at about $28,000. Pale Fire Capital SE bought a new stake in shares of Cidara Therapeutics during the third quarter valued at about $51,000. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of Cidara Therapeutics by 25.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 79,119 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 15,912 shares in the last quarter. 35.82% of the stock is currently owned by institutional investors.
About Cidara Therapeutics
Cidara Therapeutics, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
See Also
- Five stocks we like better than Cidara Therapeutics
- Following Congress Stock Trades
- High-Yield Texas Instruments Could Hit New Highs Soon
- What is a Special Dividend?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What Are Dividends? Buy the Best Dividend Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.